Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-26 @ 11:10 AM
Ignite Modification Date: 2025-12-26 @ 11:10 AM
NCT ID: NCT02220712
Description: Only treatment-emergent adverse events (TEAEs) were assessed for this trial.
Frequency Threshold: 5
Time Frame: 20 weeks of treatment period + posttreatment observation period (57 days after administration of the fifth IMD)
Study: NCT02220712
Study Brief: A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
OPC-14597 IMD Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals 0 None 2 17 15 17 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Schizophrenia NON_SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA Ver. 17.0 View
Colon cancer NON_SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA Ver. 17.0 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Nasopharyngitis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA Ver. 17.0 View
Pharyngitis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA Ver. 17.0 View
Diabetes mellitus NON_SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA Ver. 17.0 View
Hyperlipidaemia NON_SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA Ver. 17.0 View
Schizophrenia NON_SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA Ver. 17.0 View
Insomnia NON_SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA Ver. 17.0 View
Headache NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA Ver. 17.0 View
Dyskinesia NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA Ver. 17.0 View
Tremor NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA Ver. 17.0 View
Sinus bradycardia NON_SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA Ver. 17.0 View
Abdominal pain NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA Ver. 17.0 View
Nausea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA Ver. 17.0 View
Hepatic function abnormal NON_SYSTEMATIC_ASSESSMENT Hepatobiliary disorders MedDRA Ver. 17.0 View
Injection site pain NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 17.0 View
Injection site induration NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA Ver. 17.0 View
Injection site swelling NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 17.0 View
Injection site erythema NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 17.0 View
Injection site discomfort NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 17.0 View
Weight increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Blood glucose increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Blood insulin increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Blood thyroid stimulating hormone increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Glucose urine present NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Glycosylated haemoglobin increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Blood alkaline phosphatase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA Ver. 17.0 View
Thermal burn NON_SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA Ver. 17.0 View